NeoGenomics (NEO) just delivered third quarter 2026 results that topped expectations, with double digit year over year revenue growth, improved adjusted earnings guidance, and a planned CEO transition that reshapes the leadership picture. NeoGenomics’ latest earnings surprise has arrived after a powerful run, with the share price delivering a 52.98% year to date share price return and a 75.00% total shareholder return over one year, even though the 5 year total shareholder return is still...
Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.
NeoGenomics (NEO) expanded its collaboration with Indica Labs to scale digital pathology operations
Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.
NeoGenomics, Inc. recently amended its bylaws to expand its Board to up to eleven directors, issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth, and outlined plans to increase full-year revenue guidance. The company also unveiled a planned leadership transition that will see President and COO Warren Stone become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the...
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their CEOs would soon step down.
Investing.com -- NeoGenomics Inc (NASDAQ:NEO) shares fell 3.6% in after-hours trading Monday following the company’s announcement of a CEO transition, despite preliminary third quarter revenue results that exceeded analyst expectations.
NeoGenomics stock reaction to precision oncology expansion plan NeoGenomics (NEO) drew investor attention after executives detailed plans to expand in community-based precision oncology, highlighting next-generation sequencing, minimal residual disease testing, and workflow tools for community physicians as key focus areas. NeoGenomics shares have been on a strong run recently, with a 30-day share price return of 14.31% and a 90-day gain of 69.22%. The 1-year total shareholder return of...
Earlier in 2026, NeoGenomics executives detailed plans to expand in community-based precision oncology, with a particular push into next-generation sequencing, minimal residual disease testing, and workflow tools for community oncologists. An important takeaway is that NGS already represents a relatively small share of test volume but a much larger portion of clinical revenue, underscoring how mix shift toward advanced assays could reshape the company’s earnings profile. We’ll now examine...
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at t
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.
FORT MYERS, Fla., September 01, 2026--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.
Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high. Shares are up more than 170% over the past 52 weeks. NEO maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and...
FORT MYERS, Fla., August 26, 2026--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
Earnings, drug development, and healthcare reimbursement fueled the stock rallies.
Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.